Earnings calendar/NVZMF
NOVOZYMES AS/FI (NVZMF)
NOVOZYMES AS/FI (NVZMF) Q2 FY2026 (quarter ended ): revenue EUR 1.1B, net income EUR 171.0M, diluted EPS EUR 0.37. Trailing four filed quarters ( to ): revenue EUR 4.3B, diluted EPS EUR 1.36. Figures as reported, in EUR. NOVOZYMES AS/FI is based in Denmark; NVZMF is the listing on Other OTC, quoted in USD.
Quarter-by-quarter results read from the company's own filed statements — period end, filing date, diluted EPS, revenue and year-over-year change. Consensus estimates are shown only where one exists.
Latest filed quarter
The most recent quarter NOVOZYMES AS/FI has filed, from EvidInvest's standardized statements.
Period end
Jun 30, 2026
Q2 FY2026
Filed
Jun 30, 2026
Filing date on record
EPS (diluted)
$0.37
Est. $0.62 · -40.0%
Revenue
$1.11B
Est. $1.26B · -11.9%
Net income
$171.0M
As filed
EPS YoY
+27.6%
vs quarter ended 2025-06-30
Revenue YoY
+9.1%
vs quarter ended 2025-06-30
Next report
Dec 29, 2026
Estimated from filing cadence
Run-rate
Trailing twelve months, summed from the last four filed quarters.
TTM EPS (diluted)
$1.36
2025-09-30 through 2026-06-30
TTM revenue
$4.29B
2025-09-30 through 2026-06-30
Filed quarters
40
On record here
Next revenue estimate
—
No estimate on record
Filed quarters
One row per filed statement, newest first
| Period end | Filed | EPS diluted | Revenue | EPS YoY | Revenue YoY | Est. EPS | Surprise |
|---|---|---|---|---|---|---|---|
| 2026-06-30Q2 FY2026 | 2026-06-30 | $0.37 | $1.11B | +27.6% | +9.1% | $0.62 | -40.0% |
| 2026-03-31Q1 FY2026 | 2026-03-31 | $0.43 | $1.12B | +7.5% | +4.0% | $0.81 | -46.8% |
| 2025-12-31Q4 FY2025 | 2025-12-31 | $0.26 | $996.6M | -50.9% | -50.2% | $0.79 | -67.1% |
| 2025-09-30Q3 FY2025 | 2025-09-30 | $0.30 | $1.06B | -65.1% | -84.4% | — | — |
| 2025-06-30Q2 FY2025 | 2025-06-30 | $0.29 | $1.02B | -66.3% | -85.1% | — | — |
| 2025-03-31Q1 FY2025 | 2025-03-31 | $0.40 | $1.08B | -53.5% | -84.2% | — | — |
| 2024-12-31Q4 FY2024 | 2024-12-31 | $0.53 | $2.00B | -78.9% | -56.5% | — | — |
| 2024-06-30Q2 FY2024 | 2024-06-30 | $0.86 | $6.83B | -60.6% | +62.0% | — | — |
| 2024-03-31Q1 FY2024 | 2024-03-31 | $0.86 | $6.83B | -69.5% | +47.8% | — | — |
| 2023-12-31Q4 FY2023 | 2023-12-31 | $2.51 | $4.60B | -21.1% | +1.6% | — | — |
| 2023-09-30Q3 FY2023 | 2023-09-30 | $3.37 | $4.46B | -18.6% | +2.0% | — | — |
| 2023-06-30Q2 FY2023 | 2023-06-30 | $2.18 | $4.22B | -24.8% | -1.6% | — | — |
| 2023-03-31Q1 FY2023 | 2023-03-31 | $2.82 | $4.62B | -5.4% | +5.8% | — | — |
| 2022-12-31Q4 FY2022 | 2022-12-31 | $3.18 | $4.53B | +42.0% | +18.1% | — | — |
| 2022-09-30Q3 FY2022 | 2022-09-30 | $4.14 | $4.37B | +37.5% | +16.1% | — | — |
| 2022-06-30Q2 FY2022 | 2022-06-30 | $2.90 | $4.29B | +2.5% | +19.7% | — | — |
| 2022-03-31Q1 FY2022 | 2022-03-31 | $2.98 | $4.37B | -5.4% | +15.8% | — | — |
| 2021-12-31Q4 FY2021 | 2021-12-31 | $2.24 | $3.83B | -3.9% | +11.3% | — | — |
| 2021-09-30Q3 FY2021 | 2021-09-30 | $3.01 | $3.76B | +19.0% | +9.6% | — | — |
| 2021-06-30Q2 FY2021 | 2021-06-30 | $2.83 | $3.58B | +24.1% | +6.9% | — | — |
| 2021-03-31Q1 FY2021 | 2021-03-31 | $3.15 | $3.78B | +9.4% | -0.3% | — | — |
| 2020-12-31Q4 FY2020 | 2020-12-31 | $2.33 | $3.45B | -28.3% | -7.6% | — | — |
| 2020-09-30Q3 FY2020 | 2020-09-30 | $2.53 | $3.43B | +13.5% | -7.4% | — | — |
| 2020-06-30Q2 FY2020 | 2020-06-30 | $2.28 | $3.35B | -26.9% | -3.2% | — | — |
| 2020-03-31Q1 FY2020 | 2020-03-31 | $2.88 | $3.79B | +19.5% | +8.8% | — | — |
| 2019-12-31Q4 FY2019 | 2019-12-31 | $3.25 | $3.73B | +12.8% | +0.5% | — | — |
| 2019-09-30Q3 FY2019 | 2019-09-30 | $2.23 | $3.70B | -19.2% | +1.3% | — | — |
| 2019-06-30Q2 FY2019 | 2019-06-30 | $3.12 | $3.46B | +17.7% | -1.1% | — | — |
| 2019-03-31Q1 FY2019 | 2019-03-31 | $2.41 | $3.48B | -11.7% | -1.1% | — | — |
| 2018-12-31Q4 FY2018 | 2018-12-31 | $2.88 | $3.71B | +7.5% | +1.1% | — | — |
| 2018-09-30Q3 FY2018 | 2018-09-30 | $2.76 | $3.66B | 0.0% | +2.2% | — | — |
| 2018-06-30Q2 FY2018 | 2018-06-30 | $2.65 | $3.50B | +7.3% | -1.1% | — | — |
| 2018-03-31Q1 FY2018 | 2018-03-31 | $2.73 | $3.52B | +5.8% | -5.9% | — | — |
| 2017-12-31Q4 FY2017 | 2017-12-31 | $2.68 | $3.67B | 0.0% | -1.1% | — | — |
| 2017-09-30Q3 FY2017 | 2017-09-30 | $2.76 | $3.58B | +11.3% | +5.6% | — | — |
| 2017-06-30Q2 FY2017 | 2017-06-30 | $2.47 | $3.54B | +0.4% | +3.2% | — | — |
| 2017-03-31Q1 FY2017 | 2017-03-31 | $2.58 | $3.74B | — | — | — | — |
| 2016-12-31Q4 FY2016 | 2016-12-31 | $2.68 | $3.71B | — | — | — | — |
| 2016-09-30Q3 FY2016 | 2016-09-30 | $2.48 | $3.39B | — | — | — | — |
| 2016-06-30Q2 FY2016 | 2016-06-30 | $2.46 | $3.43B | — | — | — | — |
Need NVZMF data in your own agent or pipeline?
The earnings data on this page — report dates, filed EPS/revenue actuals and run-rate history — is also available programmatically through the EvidInvest MCP server & financial data API for Claude, Cursor, or any MCP client and HTTP pipeline.